RPG Life Sciences Limited has announced its financial results for the fourth quarter and for the financial year ended March 31, 2026.

In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth compared to Rs 143.1 crore in Q4 FY25, while maintaining a healthy EBITDA margin of 25.6%. For the full year FY26, revenue from operations stood at Rs 707.5 crore, up 8.3% from Rs 653.4 crore in FY25, with an EBITDA margin of 24.4%.

The Domestic Formulations (DF) business delivered strong growth of 18.2% during the quarter, significantly outpacing the Indian Pharma Market, which grew by 10.1% in the same period, reflecting a 1.8 times growth over the market. The company noted that this performance has positioned it as the fourth fastest growing pharma company in India.

For FY26, the DF segment, contributing nearly 70% of total sales, recorded a growth of 13.7%, outperforming the broader market growth of 8.6%, driven by strong traction across key therapy areas including nephrology, oncology, and pain management.

The API division demonstrated a strong comeback in Q4, registering a growth of 144.3% following the resumption of operations at its manufacturing unit. The recovery comes after the fire incident at its API plant in January 2025 and subsequent restoration of the facility.

Commenting on the results and the business outlook, Ashok Nair, Managing Director, RPG Life Sciences Ltd., said, “Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. The resilience demonstrated by our API business during the year reflects the strength of our teams and the robustness of our operations.

Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness. We are also working towards widening our global footprint across fast-growing markets.”

The Board of Directors at its meeting held today has recommended a Final dividend of Rs 24 per equity share i.e. 300% on the face value of Rs 8 each for FY25-26, subject to approval of shareholders.